Are angiotensin II receptor blockers more efficacious than placebo in heart failure? Implications of ELITE-2

被引：10

作者：

Berry, C

Norrie, J

McMurray, JJV

机构：

[1] Univ Glasgow, Clin Res Initiat Heart Failure, Glasgow G12 8QQ, Lanark, Scotland

[2] Univ Glasgow, Robertson Ctr Biostat, Glasgow G12 8QQ, Lanark, Scotland

来源：

AMERICAN JOURNAL OF CARDIOLOGY | 2001年 / 87卷 / 05期

关键词：

D O I：

10.1016/S0002-9149(00)01439-9

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

引用

页码：606 / 607

页数：2

共 13 条

[1]

Rationale and design of the Valsartan Heart Failure Trial: A large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure [J].

Cohn, JN ;

Tognoni, G ;

Glazer, RD ;

Spormann, D ;

Hester, A .

JOURNAL OF CARDIAC FAILURE, 1999, 5 (02) :155-160

[2]

Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction:: The OPTIMAAL trial design [J].

Dickstein, K ;

Kjekshus, J .

AMERICAN JOURNAL OF CARDIOLOGY, 1999, 83 (04) :477-481

[3]

Trials to assess equivalence: The importance of rigorous methods [J].

Jones, E ;

Jarvis, P ;

Lewis, JA ;

Ebbutt, AF .

BMJ-BRITISH MEDICAL JOURNAL, 1996, 313 (7048) :36-39

[4]

Comparison of candesartan, enalapril, and their combination in congestive heart failure - Randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study - The RESOLVD pilot study investigators [J].

McKelvie, RS ;

Yusuf, S ;

Pericak, D ;

Avezum, A ;

Burns, RJ ;

Probstfield, J ;

Tsuyuki, RT ;

White, M ;

Rouleau, J ;

Latini, R ;

Maggioni, A ;

Young, J ;

Pogue, J .

CIRCULATION, 1999, 100 (10) :1056-1064

[5]

Angiotensin-converting enzyme-independent contraction to angiotensin I in human resistance arteries [J].

Padmanabhan, N ;

Jardine, AG ;

McGrath, JC ;

Connell, JMC .

CIRCULATION, 1999, 99 (22) :2914-2920

[6]

Valsartan in Acute Myocardial Infarction trial (VALIANT): Rationale and design [J].

Pfeffer, MA ;

McMurray, J ;

Leizorovicz, A ;

Maggioni, AP ;

Rouleau, JL ;

Van de Werf, F ;

Henis, M ;

Neuhart, E ;

Gallo, P ;

Edwards, S ;

Sellers, MA ;

Velazquez, E ;

Califf, R .

AMERICAN HEART JOURNAL, 2000, 140 (05) :727-734

[7]

Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II [J].

Pitt, B ;

Poole-Wilson, PA ;

Segal, R ;

Martinez, FA ;

Dickstein, K ;

Camm, AJ ;

Konstam, MA ;

Riegger, G ;

Klinger, GH ;

Neaton, J ;

Sharma, D ;

Thiyagarajan, B .

LANCET, 2000, 355 (9215) :1582-1587

[8]

Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: Rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study - ELITE II [J].

Pitt, B ;

Poole-Wilson, P ;

Segal, R ;

Martinez, FA ;

Dickstein, K ;

Camm, AJ ;

Konstam, MA ;

Riegger, G ;

Klinger, GH ;

Neaton, J ;

Sharma, D ;

Thiyagarajan, B .

JOURNAL OF CARDIAC FAILURE, 1999, 5 (02) :146-154

[9]

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE) [J].

Pitt, B ;

Segal, R ;

Martinez, FA ;

Meurers, G ;

Cowley, AJ ;

Thomas, I ;

Deedwania, PC ;

Ney, DE ;

Snavely, DB ;

Chang, PI .

LANCET, 1997, 349 (9054) :747-752

[10]

Swedberg K, 1999, J Card Fail, V5, P276, DOI 10.1016/S1071-9164(99)90013-1

← 1 2 →